908 Devices Boosts Revenue Outlook After NIRLAB Acquisition
Event summary
- 908 Devices reported Q1 2026 revenue of $13.4M, up 14% YoY.
- Recurring revenue accounted for 30% of total revenues.
- Adjusted gross margin improved by 290 basis points to 57%.
- Acquired NIRLAB AG post-quarter to expand narcotics detection market.
- Raised 2026 revenue outlook to $67M–$70M, up 19–25% YoY.
The big picture
908 Devices' acquisition of NIRLAB AG targets the lower-cost segment of the narcotics detection market, aligning with broader trends in defense and public safety technology. The deal underscores the company's focus on recurring revenue models, a strategic pivot amid increasing competition in handheld chemical analysis tools. With a strong cash position and improved margins, 908 Devices is positioning itself for disciplined growth in a fragmented market.
What we're watching
- Integration Risk
- How NIRLAB AG's lower-cost drug detection capabilities will integrate with 908 Devices' existing portfolio.
- Recurring Revenue Growth
- Whether the shift to software subscriptions can sustain the 30% recurring revenue share.
- Market Expansion
- The pace at which NIRLAB AG's international mix will drive new customer acquisitions.
Related topics